402-334-4773

Research Trials

If you have any questions or are interested in participating in one of our clinical trials, please jot down the trial number and contact your Nebraska Cancer Specialists medical oncologist or a member of our clinical research team at 402.334.4773, or email us at clinicaltrials@nebraskacancer.com.

Download All Current Trials

  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • 7465-CL-202

    An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

    Cancer Type: Esophageal

    Lines of Therapy: 2

    Phase: 2

    View Details on ClinicalTrials.gov

  • XL092-002 (STELLAR 002)

    Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)

    Cancer Type: Renal

    Lines of Therapy: 1

    Phase: 1b

    View Details on ClinicalTrials.gov

  • 20216 (ACCRU-GI-1617, SGNTUC-017)

    20216 (ACCRU-GI-1617, SGNTUC-017) MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer

    Cancer Type: Colorectal

    Lines of Therapy: 3

    Biomarkers: HER2+

    Phase: 2

    View Details on ClinicalTrials.gov

  • LAGOON PM1183-C-008

    Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

    Cancer Type: SCLC

    Phase: 3

    View Details on ClinicalTrials.gov

  • CA224-127

    A Phase 3, Randomized, study of subcutaneous Nivolumab + Relatlimab Fixed-dose combination vs IV Nivolumab + Relatimab Fixed-dose combination in participants with previously untreated metastatic or unresectable melanoma.

    Cancer Type: MELANOMA

    Phase: 3

    View Details on ClinicalTrials.gov

  • GS-US-595-6184 (ASCENT-05)

    A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

    Cancer Type: BREAST

    Biomarkers: ER-, PR-, HER2-

    Phase: 3

    View Details on ClinicalTrials.gov

  • CAAA601A22301 (NETTER-2)

    A Phase III multi-center, randomized, open-label study to evaluate the efficacy and safey of Lutathera in patients with Grade II and Grade III advanced GEP-NET

    Cancer Type: Neuroendocrine

    Lines of Therapy: 1

    Biomarkers: SSRT+

    Phase: 3, Theranostics

    View Details on ClinicalTrials.gov

  • Advaxis (ADXS-503-101)

    Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

    Cancer Type: Lung NSCLC

    Lines of Therapy: 3, 2, 4

    Phase: 1, 2

    View Details on ClinicalTrials.gov

  • Boehringer Ingelheim 1403-0008 (Brightline-1)

    Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

    Cancer Type: Liposarcoma

    Lines of Therapy: 1

    Biomarkers: MDM2 amplification

    Phase: 2, 3

    View Details on ClinicalTrials.gov

  • GS-US-592-6238

    A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1

    Cancer Type: BREAST

    Lines of Therapy: 1

    Biomarkers: HR-, HER2-, PR-

    Phase: 3

    View Details on ClinicalTrials.gov